Pidnarulex
Phase 1Small molecule
Pidnarulex is one of 10 small molecule programs targeting Metastatic Colorectal Adenocarcinoma. It is currently in Phase 1.
3
Indications
5
Total Trials
4
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Metastatic Malignant Solid Neoplasm
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Taxol
TevaPhase 2
Tasigna
AAzurity Pharmaceuticals
Phase 2
Herceptin
RochePhase 1
Keytruda
Merck & Co.Phase 1
Hycamtin
MMeitheal
Preclinical
Veliparib
AbbViePreclinical
Pidnarulex
NNational Cancer Institute (NCI)
Phase 1
Edodekin Alfa
NNational Cancer Institute (NCI)
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial
Anatomic Stage III Breast Cancer AJCC v81 trial
Metastatic Malignant Solid Neoplasm1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pidnarulex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)